NCT02209792终止2 期
A Randomised, Double-blind, Placebo-controlled, Five* Parallel Groups, Dose Finding Study of BIRB 796 BS (10, 20, 30, and 60 mg*) Administered Twice a Day Orally Over 8 Weeks in Patients With Moderate to Severe Crohn's Disease Followed by a 18 Weeks Treatment Extension in Patients With Clinical Remission or Clinical Response After 8 Weeks Treatment With the Respective Dose of BIRB 796 BS - Extension Phase. * Subsequent to Amendment 4 (Dated 11 Jun 2002) a 60 mg b.i.d. Group Was Included.
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 284
- 主要终点
- Clinical Remission defined as Crohn's Disease Activity Index (CDAI) < 150
研究概览
简要总结
The primary objective of this extension study was to obtain long-term safety data for BIRB 796 BS in patients with moderate to severe Crohn's disease after 26 weeks of treatment. Secondary objectives were the evaluation of efficacy of BIRB 796 BS to induce clinical remission and response over 26 weeks of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient of 18 to 65 years of age
- •Provision of written informed consent in accordance with Good Clinical Practice and local legislation prior to any study procedures
- •Diagnosis of Crohn's disease documented for at least 6 months. Preferably, inflammatory activity of the bowel should be confirmed by endoscopy within the last 3 months
- •Moderate to severe Crohn's disease, CDAI ≥220 to ≤450, at baseline (visit 2)
- •Any of the following therapy, provided the respective criteria for dosage, duration and stability were satisfied:
- •Prednisone or other systemic corticosteroids for at least 12 weeks with a stable oral dosage ≤25 mg/d or equivalent for at least two weeks prior to visit 2
- •Budesonide with a stable dose of ≤ 9 mg/d for at least 2 weeks prior to visit 2 (changed by amendment 1, dated 16 January 2002)
- •5-Aminosalicylic Acid drugs/derivatives, provided they were given for 3 months or more and the dosage was stable for at least 4 weeks prior to visit 2
- •6-Mercaptopurine or azathioprine, provided they were taken for 6 months or more and the dosage was stable for at least 12 weeks prior to visit 2
- •Methotrexate, provided it was taken for 6 months or more and the dosage was stable and ≤25 mg per week for at least 12 weeks prior to visit 2
- •The following patients were included in the 18-week treatment extension:
- •Patients who received BIRB 796 BS for 8 weeks and reached:
- •Clinical remission (defined as CDAI <150) after 8 weeks or
- •Clinical response (reduction of CDAI ≥70) after 8 weeks
- •Patients who were willing to continue with their treatment
排除标准
- •Pregnancy (to be excluded at visit 2 by urine β-human chorion-gonadotropin-test in women of childbearing potential) or breast feeding
- •Female patients of childbearing potential (not 6 months post-menopausal or surgically sterilised) not using an approved form of birth control (hormonal contraceptives orally or in depot, intrauterine device)
- •Patients without signs of inflammation of the bowel in the initial colonoscopy of the substudy
- •Patients with colostomy or ileostomy
- •Planned or needed surgery during the conduct of the trial due to Crohn's disease or for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage
- •Known or suggested severe fixed symptomatic stenosis of the small or large intestine
- •Severe underlying disease in particular of the GI tract (e.g. irritable bowel syndrome, celiac disease, infectious colitis)
- •Patients with pathogens or Clostridium difficile toxin detected in the stool culture in the screening period
- •Other infectious, ischemic, or immunological diseases with gastrointestinal involvement
- •Patients with short bowel syndrome
- •Patients who had had a treatment failure with a tumor necrosis factor (TNF)-blocking agent. Treatment failure was defined as not achieving a clinical response (improvement of ≥70 points in CDAI within 4 weeks) in a clinical trial or - in clinical practice -discontinuation of the TNF-blocking agent due to ineffectiveness (changed according to amendment 1, dated 16 January 2002)
- •Treatment with cyclosporine A within 12 weeks prior to visit 2
- •Last dose given within the specified time period before visit 2 for the following compounds:
- •infliximab (Remicade®): 8 weeks,
- •investigational agent: 4 weeks or 5 half-lives, whichever is longer
- •Treatment with anti-inflammatory medication deviating from the criteria for dosage, and stability as provided in the inclusion criteria
- •Patients treated with any of the following therapy:
- •antibiotics provided the dosage had not been stable within 2 weeks prior to visit 2;
- •parenteral or elemental diet;
- •intrarectal therapy for Crohn's disease 2 weeks prior to visit 2 (added by amendment 1, dated 16 January 2002)
- •Treatment with:
- •Nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to visit 2;
- •Acetylsalicylic acid >100 mg/d;
- •Paracetamol (acetaminophen) >3 g/day;
- •Drug classified as proton pump inhibitor: 7 days prior to visit
- •This exclusion criterion was deleted after amendment 2 dated 11 June
- •Drug classified as H2-receptor-blocker or antacid: 2 days prior to visit
- •This exclusion criterion was deleted after amendment 2 dated 11 June
- •Active infection or serious infectious diseases resulting in hospitalisation or requiring systemic anti-infective therapy within 4 weeks before visit 2
- •Serologic evidence of active hepatitis B and/or C
- •Known HIV-infection
- •History of prior tuberculosis infection or suspicion of active infection at screening based on chest X-ray done within 6 months prior to treatment phase
- •History of cardiovascular, renal, neurologic, psychiatric, liver, immunologic, or endocrine dysfunction if they were clinically significant. A clinically significant disease was defined as one which, in the opinion of the investigator, may have either put the patient at risk because of participation in the study or as a disease which may have influenced the results of the study or the patient's ability to participate in the study
- •Recent history of heart failure (one year or less) or myocardial infarction or patients with any cardiac arrhythmia requiring drug therapy (changed by amendment 1, dated 16 January 2002)
- •ECG results outside of the reference range of clinical relevance including, but not limited to QTcB >480 msec, PR interval >240 msec, QRS interval >110 msec
- •History of malignant disease in the last 5 years or suspicion of active malignant disease except successfully treated squamous or basal cell carcinoma of the skin and except patients with cervical carcinoma in situ who have had adequate treatment and follow up
- •Clinically significant abnormal baseline haematology, blood chemistry or urinalysis if the abnormality defines a disease listed as an exclusion criterion
- •Any of the following specific laboratory abnormalities at visit 1:
- •alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than upper limit of normal range (ULN)
- •Total bilirubin greater than ULN except for patients with documented Gilbert's disease
- •Gamma-glutamyltransferase, alkaline phosphatase or lactate dehydrogenase greater than 1.5 x ULN
- •White blood cell count greater than 1.5 ULN which was not due to Crohn's disease as assessed by the investigator
- •Serum creatinine above 1.5 x ULN
- •History of drug or alcohol abuse within the past two years or active drug or alcohol abuse
- •Participation in another clinical trial within 4 weeks or 5 half-lives of the respective investigational agent, whichever was longer
- •Hypersensitivity to trial drug
- •Inability to comply with the protocol
研究组 & 干预措施
BIRB 796 BS, medium dose 2
Experimental
2 x 5 mg + 20 mg b.i.d.
干预措施: BIBR 796 BS, 5 mg (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
BIRB 796 BS, low dose
Experimental
2 x 5 mg b.i.d.
干预措施: Placebo (Drug)
BIRB 796 BS, low dose
Experimental
2 x 5 mg b.i.d.
干预措施: BIBR 796 BS, 5 mg (Drug)
BIRB 796 BS, medium dose 1
Experimental
20 mg b.i.d.
干预措施: Placebo (Drug)
BIRB 796 BS, medium dose 1
Experimental
20 mg b.i.d.
干预措施: BIBR 796 BS, 20 mg (Drug)
BIRB 796 BS, medium dose 2
Experimental
2 x 5 mg + 20 mg b.i.d.
干预措施: BIBR 796 BS, 20 mg (Drug)
BIRB 796 BS, high dose
Experimental
3 x 20 mg b.i.d.
干预措施: BIBR 796 BS, 20 mg (Drug)
结局指标
主要结局
Clinical Remission defined as Crohn's Disease Activity Index (CDAI) < 150
时间窗: at week 8
次要结局
- Number of patients with adverse events(up to 40 weeks)
- Number of drop-outs due to treatment failure(up to 26 weeks)
- Changes from baseline in C-reactive protein (CRP) measurements(up to 26 weeks)
- Changes from baseline in the daily corticosteroid dose(after week 10)
- Changes from baseline in the CDAI score(up to 26 weeks)
- Changes from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) score(up to 26 weeks)
- Number of patients with 50% fistulae reduction(up to 26 weeks)
- Changes from baseline in the number of draining fistulae(up to 26 weeks)
- Number of patients with clinically relevant changes in laboratory parameters(up to week 38)
- Number of patients with relevant findings in electrocardiogram (ECG)(up to 26 weeks)
- Extended clinical response (defined as a reduction of CDAI score ≥ 100)(week 10 to 26)
- Duration of maintenance of clinical response(up to 26 weeks)
- Time to clinical remission(up to 26 weeks)
- Clinical remission (defined as a CDAI score below 150)(at week 26)
- Stabilised clinical remission at the end of the main treatment phase(at week 8 and 10)
- Duration of maintenance of clinical remission(up to 26 weeks)
- Clinical response (defined as a reduction of CDAI score ≥70)(up to 26 weeks)
- Time to clinical response(up to 26 weeks)
- Time to extended clinical response(week 10 to 26)
- Duration of maintenance of extended clinical response(week 10 to 26)
- Changes from baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) score(at the end of week 8)
- Changes from baseline in the histological scoring of biopsy specimens(at the end of week 8)
研究者
相似试验
已完成
3 期
Long-Term Evaluation of BIIB067 (Tofersen)ALS Caused by Superoxide Dismutase 1 (SOD1) MutationNCT03070119Biogen139
终止
1 期
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisNCT04288856Biogen75
已完成
1 期
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120NeoplasmsNCT00715403Boehringer Ingelheim41
已完成
3 期
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT01368081Boehringer Ingelheim1,162
已完成
3 期
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis, Relapsing-RemittingNCT02555215Biogen20